Imago BioSciences to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Imago BioSciences, Inc. (Imago), a clinical stage biopharmaceutical company developing innovative treatments for myeloid diseases, today announced that executive leadership will be participating in the following upcoming investor conferences:

• SVB Leerink 10th Annual Global Healthcare Conference
  Date: Feb. 23, 2021
  
  
• Cowen 41st Annual Healthcare Conference
  Date: March 1, 2021

About Imago BioSciences

Imago BioSciences is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapeutics for the treatment of hematologic disorders. Imago has developed a series of compounds that inhibit LSD1, an epigenetic enzyme critical for cancer stem cell function and blood cell differentiation. The company is advancing the clinical development of its first LSD1 inhibitor, bomedemstat, for the treatment of myeloid neoplasms. Imago is backed by leading private, public and strategic investors including a fund managed by Blackstone Life Sciences, Frazier Healthcare Partners, Omega Funds, Farallon Capital Management, L.L.C., funds and accounts advised by T. Rowe Price Associates, Inc., and funds and accounts managed by Blackrock Advisors, LLC. The company is based in South San Francisco, California. To learn more, visit www.imagobio.com, www.myelofibrosisclinicalstudy.com, www.etclinicalstudy.com and follow us on Twitter @ImagoBioRx, Facebook and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210209005327/en/

Media Contact:
Steve Kunszabo
Canale Communications
[email protected]

Investor Contact:
Matthew Plunkett, PhD,
Chief Financial Officer, Imago Biosciences
[email protected]

Source: Imago BioSciences, Inc.

You May Also Be Interested In

• Metropolitan Issues Statement on Release of 2027-2028 Guidelines, ROD for Colorado River Operations
• Zum Appoints Matthew Klein as VP of Software Sales
• BioNxt Solutions Inc. Announces Closing of Extension of Convertible Debentures and Issuance of Warrants